The pharmaceutical industry relies heavily on its supply chain, but this chain can also have a significant environmental impact due to common factors like high emissions or packaging waste.
This article explores current OSD development and manufacturing trends from a CDMO perspective, including the evolution of ...
Corden Pharma Colorado Inc., a developer and manufacturer of peptide drug substances, has leased the 64,000-square-foot 5505 ...
Virginia attracted $12 billion in pharmaceutical manufacturing investments in 2025, leveraging site readiness, workforce training, and strong infrastructure.
With more than $270 billion in commitments to date, a new wave of pharmaceutical manufacturing is slated to hit the US. At least, that’s what the industry is trying to project. Behind the curtain of ...
Chakravarthi AVPS, Chairman of the Federation of Pharma Entrepreneurs, provides an overview of global strategies to accelerate access to innovative therapies, bridging equity, regulation, and ...
McKinney explains how tariff concerns drove last year’s manufacturing surge and why Atradius expects a period of stabilization ahead. He also discusses how companies are weighing the risk of future ...
The biopharma industry has spent much of this year grappling with fast-moving changes related to the Trump administration's trade policies. On Thursday, without warning, came another jolt. “Starting ...
SANTA ANA, Calif, Dec. 18, 2025 /PRNewswire/ -- Robinson Pharma Inc., a leading USA-based contract manufacturer of dietary supplements, today announced a significant expansion of its manufacturing ...
A degree of uncertainty reigns over the implementation of regulations imposed by US President Donald Trump that aim to bolster pharmaceutical manufacturing in the US, market analysis suggests. Trump ...
Pharmaceutical giants AstraZeneca, Eli Lilly & Co. and Merck & Co. have committed a cumulative $120 million to develop a workforce training center for advanced pharmaceutical manufacturing in Central ...
Asahi Kasei acquires Aicuris for €780M ($920M), adding anti-infective assets to its transplant and nephrology specialty pharmaceutical platform.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results